Introduction
Premature delivery is an important obstetrical complication associated with increase perinatal mortality and morbidity. There is good evidence that prostaglandins play an important role in the pathogenesis of premature labor [14] . The nonsteroid anti-inflammatory agent indomethacin, is a potent inhibitor of prostaglandin biosynthesis in the body and it is also an established fact that contractions may be inhibited by indomethacin [20] . In first part of the study we have shown in a very large uncontrolled group of patients the efficacy and safety of the drug in arresting premature labor, the same as others [4, 8, 25, 29] . The purpose of the second part of the study was to test in a controlled double-blind fashion the efficacy of indomethacin in suppressing the premature labor.
Material and methods
Patients included in the trial were between [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] weeks gestation who presented with painful, regular uterine contractions occurring at intervals of two or more contractions in 10 minutes, recorded for at least 30 minutes by external tocography, or contractions accompanied by effacement and/or dilation of the cervix at least 1-2 cm, but not more than 4 cm. The patients were informed about the aim of the investigation. All patients have had ultrasonic examination before treatment. We excluded patients with pre-eclampsia, diabetes mellitus, twins, cardiac disease, antepartum hemorrhage, ruptured membranes, intra-uterine infections or intra-uterine growth retardation. Indomethacin or placebo were allocated at random. The code key was not available to the investigators before completion of the study. The indomethacin group included 18 patients and the placebo group also included 18 patients. After an initial registration of contractions for 30 minutes, indomethacin or placebo was begun. Treatment consisted of a rectal suppository of 100 mg and then capsules of 25 mg 4 times daily for 24 hours. If uterine contractions continued after the insertion of the first suppository, the patient received an additional 100mg suppository (from the same envelope) after 1 hour, and then the treatment was continued orally. The total dosage of indomethacin was 200-300 mg in 24 hours. If there were further indications of premature delivery and progressive dilation of the cervix 2 hours after the first suppository, this was considered as a treatment failure and other therapy for cessation of premature labor was given. The uterine activity was recorded with a cardiotocograph. The matemal heart rate, maternal blood pressure and fetal heart rate were recorded. During hospitalization, both the indomethacin and placebo treated patients were kept at bed rest. If they had no contractions after the completion of treatment during 3 days, they were discharged from the Tab. I. Clinical data (mean ± SEM) of the patient pupulation of the indomethacin and placebo group. hospital. The treatment was considered successful if labor was arrested and delivery was delayed for more than 7 days. It was considered to be of moderate value if labor was arrested from 48 hours to 7 days, and considered unsuccessful if delivery took place within 48 hours. The criterion for prematurity was a birth age of less than 37 week gestation confirmed at delivery using the DUBOWITZ assessment scale [6] . The pediatrician examined each newborn immediately after delivery, during hospitalization and in follow up of 6 months. There was no significant difference between the 2 groups in respect to age, parity arid gestational age (Tab. I). The delay between the initiation of the indomethacin and placebo therapy and the delivery, weight and maturity of the newborn were the criteria for evaluating the differences between the two treatments.
Results
Effect of treatment is summarized in Tab. II. In the indomethacin group treatment was successful (contractions stopped completely for more than 1 week) in 15 of 18 patients (83.3%), of moderate value (3-7 days) in 2 of 18 patients (11.1%) and unsuccessful (delivery within 48
Tab. II. Effect of treatment.
hours) in 1 of 18 patients (5.6%). In the placebo group the results were successful in 3 of 18 patients (16.6%), of moderate value in 1 of 18 patients (5.6%) and unsuccessful in 14 of 18 patients (77.8%). Among these 14 patients with unseccessful results, 8 mothers received alternative treatment (ritodrine) but 5 were delivered within 24 hours and 3 within 48 hours. The clinical outcome is presented in Tab. III. The mean duration of pregnancy for the indomethacin patients (36.4 weeks ± 0.7) was significantly greater than that for the placebo group (31.2 weeks ± 0.7) (p < 0.001). In the indomethacin group 3 newborns weighed less than 2500 g (mean birth weight for the group 2833 g ± 117g) compared with 15 newborns in the placebo group (mean birth weight for the group 2028 g ± 123 g). The mean 1 minute APGAR score in the indomethacin treated group was 9.3 ± 0.2 while in the placebo treated group it was only 7.8 ± 0.5 (p< 0.01). Respiratory distress syndrome was diagnosed in one infant in the indomethacin group and 4 in the placebo group. One infant in the indomethacin group (weight 1810g) and 2 infants in the placebo group (weight 600 and 1450 g) died from respiratory distress syndrome. The autopsy showed typical pulmonary atelectasis and hyaline mem- branes in these 3 infants. There was no evidence of 22.2% of the placebo group. The lower percentage premature closure of the ductus arteriosus or pul-can be explained by the strict criteria that we used monary hypertension. The remaining children for definition of premature labor. Using similar were normal at follow-up examination. criteria, NlEBYL et al. [18] found that patients Cesarean section was performed in 1 patient in the who failed to respond to placebo has a higher indomethacin group because of breech presenta-mean serum prostaglandin F 2 a metabolite (PGFM) tion in the first delivery and in 1 patient in the than the rest of the placebo group. The author placebo group because of prolapse of the cord, pointed to a possible predictive value of this Minor side effects as nausea, vomiting and vertigo measurements. were seen in 2 mothers in the indomethacin group. Looking from the other side the patient who In the placebo group there were no side effects, respond to placebo had the lower mean PGFM Side effects were not significantly severe to level which may suggest that these patients were warrant discontinuance of treatment. There were not in true labor. It is evident that in part of the no differences during and after therapy in either cases in which we treat what we call premature maternal blood pressure, or maternal and fetal labor all we are doing is stopping the uterine conheart rate.
tractions of a false labor. This problem, of whom to treat, will be solved only with more strict and objective criteria.
Discussion
Mean duration of pregnancy, mean birth weight and the number of mature newborns in the indoAny tocolytic agent can be used only when it methacin group was significantly greater than that needed and after its efficacy and safety to both in the placebo group and the incidence of respiramother and fetus has been proved. We believe that tory distress syndrome was higher in infants of safety of indomethacin has been proved in the first mother treated with placebo. Similar results were part of the study comprising 297 cases. We tried to obtained in study conducted by NlEBYL et al. test the efficacy of the drug in the second part of [18] . Although no conclusions can be drawn about the study using randomized controlled double-safety from such a small number of exposed blind study. It was already shown that premature babies, considering also the first part of the study, labor may be arrested with placebo in 48% of it must be stressed that no deleterious effect on patients [28] . This fact can be explained by cardiovascular, renal or coagulation system could improper criteria for diagnosis of premature labor be shown to be attributed by the indomethacin. with part of the patients not being at labor, or that The results of this part of the study indicate that bed rest alone can be effective treatment in some indomethacin is a potent inhibitor of premature cases. In the present study labor was arrested in labor.
Summary
In the etiology of premature labor prostaglandins fulfill indomethacin on premature labor was studied in a prosa significant role. It is known that indomethacin is a pective randomized double-blind study in 36 patients, strong inhibitor of prostaglandin synthesis. The effect of Eighteen patients received indomethacin and eighteen Zuckerman et al., Indemethacin, part II received placebo. 200-300 mg of indomethacin was the total dosage in a 24 hours period. The activity of the uterus was monitored with a cardiotocograph. The mean duration of pregnancy and the mean birth weight in indomethacin group (36.4 weeks, 2833 g) were both significantly greater (p < 0.001) than that in placebo group (31.2 weeks, 2028 g). In the indomethacin group 3 children weighed less than 2500 g compared with 14 in placebo group. In 15 of 18 indomethacin treated patients (83.3%) premature labor was arrested after indomethacin treatment compared with 4 of 18 in the placebo group (22.2%). The indomethacin group had a mean 1 minute APGAR score of 9.3 ± 0.2 whereas the placebo group showed a score of 7.8 ± 0.5 (p < 0.01). Three infants died Keywords: Indomethacin, premature labor, prostaglandin from respiratory distress syndrome; one in the indomethacin group (1810g) and two in the placebo group (600 and 1450 g). Autopsies in the infants demonstrated a typical picture of pulmonary atelectasis and hyaline membranes. There was no evidence of premature closure of the ductus arteriosus or pulmonary hypertension. 2 mothers in the indomethacin group suffered minor discomfort i.e. nausea, vomiting and vertigo. In both groups, no changes were noted, either during or after therapy in maternal blood pressure or maternal and fetal heart rate. Indomethacin was shown to be significantly more effective than placebo in inhibiting premature labor. synthetase inhibitor, uterine contractions. II n'y a pas eu de fermeture prematuree du canal arteriel ni d'hypertension pulmonaire. Deux meres dans le groupe indometacine ont presente des troubles minimes ä savoir nausees, vomissements et vertiges. Dans les 2 groupes, on n'a pas observe de modification de la pression arterielle maternelle ou du rythme cardiaque foetal ni pendant ni apres le traitement. II est montre que rindometacine est de fagon significative plus efficace qu'un placebo dans l'inhibition de Faccouchement premature. uterines, indometacine, inhibiteur de la synthese des
